GlassScriptPhysician profile
Susan A Gregory
NPI 1619913308
$5,034.94
in general payments reported to CMS, 2019-2025
21 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $516 · 2020: $2,976 · 2021: $330 · 2022: $812 · 2023: $355 · 2024: $45.84.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $401.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $401.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $3,387.23 | 2019-2023 | Tezspire, Fasenra, Symbicort |
| Glaxosmithkline, LLC. | $402.85 | 2019-2024 | Trelegy Ellipta, Arexvy, Nucala |
| Mylan Specialty L.P. | $235.81 | 2019-2023 | Yupelri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $208.14 | 2019-2023 | Stiolto Respimat, Spiriva Respimat |
| Genentech USA, INC. | $97.18 | 2020-2023 | Xolair |
| Insmed, INC. | $93.06 | 2019-2023 | Arikayce |
| Genzyme Corporation | $81.02 | 2019-2023 | |
| Actelion Pharmaceuticals US, INC. | $67.28 | 2019-2022 | |
| Mallinckrodt Enterprises LLC | $51.12 | 2019 | |
| Gilead Sciences, INC. | $50.56 | 2023-2024 | Veklury |
| Regeneron Healthcare Solutions, INC. | $48.94 | 2019-2022 | |
| Grifols USA, LLC | $48.27 | 2020-2022 | |
| Circassia INC. | $45.87 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $40.78 | 2022 | |
| Amgen INC. | $36.97 | 2021-2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Philips North America LLC | $32.78 | 2022 | |
| Jazz Pharmaceuticals INC. | $31.11 | 2022 | |
| United Therapeutics Corporation | $23.60 | 2022 | |
| Abbvie INC. | $19.48 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $18.34 | 2019 | |
| Celgene Corporation | $14.55 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Susan Gregory listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.